Vicore strengthens its management team
Gothenburg, August 27, 2021 – Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the addition of three experienced executives to its management team, strengthening business and commercial operations as the company’s research and development activities approach key commercial decision points.
Åsa Magnusson will join as Vicore’s Chief Commercial Officer and Mikael Nygård will join as VP of Business Development, becoming part of an enlarged management team. Jessica Shull, recently recruited Head of Digital Therapeutics will also join the Vicore management.
Åsa Magnusson will take responsibility for the company’s commercialization activities. She has more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines in areas with a high unmet medical need. She joins Vicore from Arvelle Therapeutics – a CNS and epilepsy focused biotech company based in Switzerland. Previously, Åsa worked in different international and Nordic commercial roles at Alexion, expanding innovative antibody products such as Soliris and Ultomiris. Before that, she headed the marketing of Actelion’s pulmonary arterial hypertension (PAH) pharmaceuticals, including launching Opsumit and new indications for Tracleer in the Nordic territories. Åsa will take up her role with Vicore in October 2021.
Mikael Nygård will take responsibility for the company’s business development activities, including partnering, licensing and M&A. Mikael comes with extensive experience in the healthcare industry, most recently as Head of M&A and Corporate Development at the care provider Humana AB. At Humana, Mikael has held various positions, and in his most recent role he oversaw several acquisitions and was involved in developing and implementing the company’s growth strategy. Before that, he worked in the global healthcare team at the strategy consulting firm Boston Consulting Group. Mikael holds a PhD in Neuroscience from Karolinska Institutet. Mikael will take up his role in Vicore in November 2021.
Jessica Shull joined Vicore in May 2021 to oversee the development and launch of the VP04 digital therapeutic program in IPF. Before joining Vicore, Jessica gained more than 20 years’ experience in the field of digital technologies for healthcare including development of virtual surgical devices. She is considered an authority in HTA requirements for patient-facing software and innovation adoption in Europe and abroad. In previous roles she worked on digital health best practices for the WHO and with the Digital Therapeutics Alliance she focused on digital health recognition, regulation, and policy.
Åsa Magnusson, Mikael Nygård and Jessica Shull will all join the expanded Vicore management team.
“At Vicore we are forging a powerful expanded team with a huge collective experience. As our programs in IPF and COVID-19 progress towards significant value-creating clinical milestones, we are putting in place a diligent and agile leadership with the capabilities necessary to respond to the challenges of a fast moving and evolving healthcare market.“ says Carl-Johan Dalsgaard, CEO of Vicore.
For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
This information was submitted for publication on August 27, 2021 at 08.00 CET.
About Vicore Pharma Holding AB (publ)
Vicore is a rare disease pharmaceutical company focused on fibrotic lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.
The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
Source: Vicore Pharma